The influence of asthma and COPD exacerbation on exhaled mitric oxide (FENO ) Source: Eur Respir J 2004; 24: Suppl. 48, 409s Year: 2004
Exhaled bimarkers in exacerbation of COPD Source: Annual Congress 2007 - Molecular pathogenesis: focus on COPD and asthma Year: 2007
Decreased levels of bis-S-bimane in exhaled breath condensate of COPD Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015
Characterization of airway inflammation in patients with asthma COPD overlap syndrome using FeNO levels Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015
Assessment of exhaled breath condensate pH in asthma and COPD patients with exacerbation Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010
Exhaled NO (FENO) is superior to peak-flow monitoring in predicting exacerbation in asthmatics Source: Eur Respir J 2005; 26: Suppl. 49, 118s Year: 2005
Exhaled breath condensate for evaluation of inflammation in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 35s Year: 2006
Exhaled breath temperature increases at COPD exacerbation and correlates with sputum neutrophilia Source: Annual Congress 2011 - Role of the biomarkers in airway diseases Year: 2011
Prediction of asthma exacerbations in children by FeNO and non-invasive inflammatory markers in exhaled breath condensate Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children Year: 2008
Characterization of allergic airway inflammation in patients with COPD using fractional exhaled nitric oxide levels Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013
Exhaled nitric oxide (FeNO), sputum analysis and asthma control score in children with mild to moderate asthma Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children Year: 2008
Conductivity in exhaled breath condensate of patients with asthma, COPD or cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 227s Year: 2005
Exhaled NO levels in patients with chronic cough in Japan Source: Eur Respir J 2006; 28: Suppl. 50, 671s Year: 2006
8-isoprostane in breath condensate in patients with exacerbation of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001
Longitudinal analysis between exhaled nitric oxide (FeNO), inflammatory markers (IM) in exhaled breath condensate (EBC), lung function, and control/severity of childhood asthma Source: Annual Congress 2007 - Assessing asthma severity and control in children Year: 2007
Exhaled breath condensate nitrate/nitrite in asthma, COPD and healthy controls Source: Eur Respir J 2006; 28: Suppl. 50, 283s Year: 2006
High levels of fractional exhaled nitric oxide (FeNO) in severe oral steroid-dependent asthma are associated with eosinophilia and atopy Source: Annual Congress 2009 - Airway inflammation and asthma control Year: 2009
Usefulness of fractional exhaled nitric oxide (FeNO) for early diagnosis of asthma in patients with nonspecific respiratory symptoms Source: Annual Congress 2009 - From cough to sound analysis of breathing Year: 2009
8-isoprostane and cys-leukotrienes in exhaled breath condensate (EBC) of children with asthma exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 142s Year: 2002
Content of nitric oxide in the exhaled breath condensate, induced sputum and BAL in asthma and COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 369s Year: 2006